Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

• Published in: American journal of cancer research Vol. 12; no. 4; pp. 1899 - 1911
• Main Authors: Teng, Wei, Lin, Chen-Chun, Su, Chung-Wei, Lin, Po-Ting, Hsieh, Yi-Chung, Chen, Wei-Ting, Ho, Ming-Mo, Wang, Ching-Ting, Chai, Pei-Mei, Hsieh, Jason Chia-Hsun, Lin, Chun-Yen, Lin, Shi-Ming
• Format: Journal Article
• Language: English
• Published: United States e-Century Publishing Corporation 01.01.2022
• Subjects: Original; CAR classification; atezolizumab plus bevacizumab; prognosis; hepatocellular carcinoma

Immune checkpoint inhibitors (ICIs) with atezolizumab plus bevacizumab are promising agents for unresectable hepatocellular carcinoma (HCC). We tried to guide the treatment based on recent developed CRAFITY score combining with on-treatment AFP response. Eighty-nine patients who received atezolizuma...